Pharmacologic Treatments Improve Sexual Dysfunction in Women
Background
Sexual problems are a significant concern, affecting up to 45% of individuals assigned female at birth. These issues are complex, involving both biological and psychosocial factors. While many aspects contribute, understanding the safety and efficacy of pharmacologic interventions for specific types of female sexual dysfunction, particularly those related to menopause and hypoactive sexual desire disorder (HSDD), is crucial.
Results
The review concluded that pharmacologic treatments offer safe and effective options for improving sexual desire and satisfaction. For postmenopausal individuals, local estrogen and testosterone replacement were found to be beneficial. For premenopausal individuals with HSDD, centrally-acting therapies such as flibanserin (a serotonin receptor modulator), bremelanotide (a melanocortin receptor agonist), and testosterone were highlighted as effective. Recent systematic reviews have bolstered confidence in the safety profiles of these interventions, supporting their use. The review strengthened the safety data for existing FDA-approved medications and off-label therapies, confirming their utility in addressing various forms of female sexual dysfunction.
Why It Matters
This review provides a strong evidence base for clinicians, confirming that pharmacologic interventions are safe and effective tools to improve sexual desire and satisfaction in individuals experiencing sexual dysfunction. The increased number and type of available treatments over the last decade offer more tailored options for patients. This synthesis supports the continued clinical use of these therapies and encourages further research into optimizing treatment protocols and exploring novel mechanisms to address the diverse needs of affected individuals.